Mathai Mammen
CEO, President, Treasurer & ChairmanDr. Mathai Mammen, M.D., Ph.D., serves as Senior Advisor at Advisors. Dr. Mammen is Senior Advisor of General Atlantic Service Company, L.P. from April 25, 2023, where he provides strategic counsel and advises the firm’s Life Sciences investment team and portfolio companies. He focuses on Life Sciences. Dr. Mammen currently serves as Chairman, President and Chief Executive Officer of FogPharma. Dr. Mammen is CEO, President and Chairman of Parabilis Medicines, Inc. from June 2023 and is its Treasurer and was its Secretary. Dr. Mammen is Independent Non-Executive Director of Sandoz Group AG from April 30, 2024. Dr. Mammen is Director of Kelonia Therapeutics, Inc. from March 2024. Dr. Mammen is Member of Executive Advisory Board of SalioGen Therapeutics, Inc. from May 2023. Dr. Mammen is Advisor of VR Adviser, LLC from October 2020. Dr. Mammen is Advisor of Foresite Capital Management, LLC from 2019. Dr. Mammen is Independent Director of 10x Genomics, Inc. from August 23, 2017. Dr. Mammen is Board Member and Scientific Advisor of Xaira Therapeutics, Inc. Dr. Mammen was Member of Scientific Advisory Board of Foresite Labs, LLC until November 2025. Dr. Mammen was employed at Foresite Labs, LLC until November 2025. Dr. Mammen was employed at Johnson and Johnson from June 2017 to August 2022, serving as Executive Vice President of Pharmaceuticals, R&D from 2022 to August 2022, where he had a critical role in leading Johnson and Johnson’s expansion in COVID vaccines. Prior to this. Dr. Mammen was Global Head of Research and Development of Janssen Pharmaceutical of Johnson and Johnson until December 2021. Dr. Mammen was Senior Vice President of Research and Development of Theravance Biopharma, Inc. from October 2014 to March 25, 2016. Dr. Mammen was Co-Founder of Innoviva, Inc. and was employed there from January 04, 2008 to September 30, 2014. Dr. Mammen held previous R&D roles at Merck, Inc. He co-founded Theravance in 1997. Dr. Mammen has several years of leadership experience in the biopharmaceutical industry, focusing on drug discovery, development and scaling of small and large businesses. Dr. Mammen holds a Bachelor of Science in Biochemistry and Chemistry from Dalhousie University, a Doctor of Medicine from Harvard Medical School and Massachusetts Institute of Technology Health Sciences and Technology program and a Doctor of Philosophy in Chemistry from Department of Chemistry and Chemical Biology, Harvard University.
Positions
- Company NameParabilis Medicines, Inc.Stock CodePBLSPositionCEO, President, Treasurer & ChairmanColleagues
- TLTeresa L. JurgensenExecutive VP, Secretary & General Counsel
- JMJohn McGeeScientific Co-Founder, Executive Vice President & Head of Platform
- TRThomas Rodolpho KotarakosChief Financial Officer
- RMRohin MhatreChief Technical Operations Officer
- KYKrishna YeshwantIndependent Non-Employee Director
- EMEdward M. FitzgeraldIndependent Non-Employee Director
- AAAlexis A. BorisyIndependent Non-Employee Director
- BLBarbara L. WeberIndependent Non-Employee Director
